Bispecific antibody-dependent cellular cytotoxicity of HER2/neu- overexpressing tumor cells by Fcγ/receptor type I-expressing effector cells

Cancer Research

Volumn 57, Issue 18, 1997, Pages 4008-4014

  Keler, Tibor ^a   Graziano, Robert F ^a   Mandal, Aditya ^a   Wallace, Paul K ^b   Fisher, Jan ^b   Guyre, Paul M ^b   Fanger, Michael W ^b   Deo, Yashwant M ^a  

^a MEDAREX INC   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; BREAST CARCINOMA; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, IGG; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030858083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Herlyn, D., Herlyn, M., Steplewski, Z., and Koprowski, H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur. J. Immunol., 9: 657-659, 1979.
2. Steplewski, Z., Lubeck, M. D., and Koprowski, H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science (Washington DC), 221: 865-867, 1983.
3. Hellstrom, I., Garrigues, U., Lavie, E., and Hellstrom, K. E. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res., 48: 624-627, 1988.
4. Herlyn, D., and Koprowski, H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA, 79: 4761-4765, 1982.
5. Adams, D. O., Hall, T., Steplewski, Z., and Koprowski, H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA, 81: 3506-3510, 1984.
6. Johnson, W. J., Steplewski, Z., Mathews, T. J., Hamilton, T. A., Koprowski, H., and Adams, D. O. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. J. Immunol., 136: 4704-4713, 1986.
7. Tripathi, A. K., Taplits, M., Puri, J., and Hoffman, T. Down-regulation of surface FcRI and decrease in antibody-dependent cellular cytotoxicity of cultured monocytes. J. Immunol., 146: 1309-1315, 1991.
8. Fanger, M. W., Shen, L., Graziano, R. F., and Guyre, P. M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today. 10: 92-99, 1989.
9. Key, M. E., and Haskill, J. S. Antibody dependent cellular cytotoxicity (ADCC): a potential anti-tumor defense mechanism in situ in a murine mammary adenocarcinoma. In: H. S. Koren (ed.), Macrophage Mediated Cellular Cytotoxicity, pp. 243-262. New York: Plenum Press, 1984.
10. Graziano, R. F., and Fanger, M. W. FcγRI, and FcγRII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J. Immunol., 139: 3536-3546, 1987.
11. Perussia, B., Dayton, E. T., Lazarus, R., Fanning, V., and Trichieri, G. Immune interferon induces the receptor for monomeric IgGl on human monocytic and myeloid cells. J. Exp. Med., 158: 1092-1113, 1983.
12. Guyre, P. M., Morganelli, P. M., and Miller, R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J. Clin. Invest., 72: 393-397, 1983.
13. Kerst, J. M., van de Winkel, J. G. J., Evans, A. H., de Haas, M., Slaper-Cortenbach, I. C. M., de Wit, T. P. M., von de Borne, A. E. G. K., van der School, C. E., and van Oers, R. H. J. Granulocyte colony-stimulating factor induces hFcgRI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood. 81: 1457-1464, 1993.
14. Anderson, C. L., Guyre, P. M., Whitin, J. C., Ryan, D. H., Looney, R. J., and Fanger, M. W. Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes: antibody characterization and induction of superoxide production in a monocyte cell line. J. Biol. Chem., 261: 12856-12864, 1986.
15. Graziano, R. F., Tempest, P. R., White, P., Keler, T., Deo, Y., Ghebremariam, H., Coleman, K., Pfefferkorn, L. C., Fanger, M. W., and Guyre, P. M. Construction and characterization of a humanized anti-γ-Ig receptor Type I (FcγRI) monoclonal antibody. J. Immunol., 155: 4996-5002, 1995.
16. Guyre, P. M., Graziano, R. F., Vance, B. A., Morganelli, P. M., and Fanger, M. W. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol., 143: 1650-1655, 1989.
17. Michon, J., Moutel, S., Barbet, J., Romet-Lemonne, J. L., Deo, Y. M., Fridman, W. H., and Teillaud, J. L. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti disialoganglioside/anti-FcγRI (CD64) bispecific antibody. Blood. 86: 1124-1130, 1995.
18. Ely, P., Wallace, P. K., Givan, A. L., Graziano, R. F., Guyre, P. M., and Fanger, M. W. Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood, 87: 3813-3821, 1996.
19. Frankel, A. E., Ring, D. B., Tringale, F., and Hsieh-Ma, S. T. Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biological Response Modif., 4: 273-286, 1985.
20. Slamon, D. J., Godolphin, W., Jones, L. A. Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
21. Hetzel, D. J., Wilson, T. O., Keeney, G. L., Roche, P. C., Cha, S. S., and Podratz, K. C., HER2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol., 47: 179-185, 1992.
22. Press, M. F., Pike, M. C., Hung, G., Zhou, J. Y., Ma. Y., George, J., Dietz-Band, J., James, W., Slamon, D. J., Batsakis, J. G., and El-Naggar, A. K. Amplification and overexpression of HER2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res., 54: 5675-5682, 1994.
23. Yu, D., Wang, S. S., Dulski, K. M., Tsai, C. M., Nicolson, G. L., and Hung, M. C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res., 54: 3260-3266, 1994.
24. Montiero, R., Cooper, M. D., and Kubagawa, H. Molecular heterogeneity of Fcα receptors detected by receptor-specific monoclonal antibodies. J. Immunol., 148: 1764-1770, 1992.
25. Mabonzo, A., Houssin, F., Raoul, H., LeNaour, R., Gras, G. S., Vaslin, B., Romet-Lemonne, J. L., and Dormont, D. Antibody dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 (HIV-1) by high affinity cross-linking of gp41 to human monocyte Fc IgG receptor using bispecific antibody. J. Gen. Virol., 75: 1451-1456, 1994.
26. 2 antibody containing thioether-linked Fab′ fragments. J. Immunol., 139: 2367-2375, 1987.
27. Goldstein, J., Graziano, R. F., Sundarapandiyan, K., Somasundaram, C., and Deo, Y. M. The cytolytic and cytostatic properties of an anti-human FcγRI (CD64) X epidermal growth factor bispecific fusion protein. J Immunol., 158: 872-879, 1997.
28. Valerius, T., Repp, R., de Wit, T. P. M., Berthold, S., Platzer, E., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. J. Involvement of the high-affinity receptor for IgG (FcgRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood, 82: 931-939, 1993.
29. Stockmeyer, B., Valerius, T., Repp, R., Heijnen, I. A. F. M., Buhring, H-J., Deo, Y. M., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. J. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER2/neu overexpressing breast cancer. Cancer Res., 57: 696-701, 1997.
30. Urban, J. L., Shepard, H. M., Rothstein, J. L., Sugarman, B. J., and Schreiber, H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. USA, 83: 5233-5237, 1986.
31. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V., Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., Mrozek-orlowski, M., Wardawell, K., Guyre, V., Morley, T. L., Arrizu, C., and Fanger, M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the proto-oncogene HER2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
32. Krutmann, J., Kirnbauer, R., Kock, A., Schwarz, T., Schopf, E., May, L. T., Sehgal, P. B., and Luger, T. A. Cross-linking Fc receptors on monocytes triggers IL-6 production. J. Immunol., 145: 1337-1342, 1990.
33. Debets, J. P. M. H., van de Winkel, J., Ceuppens, J. L., Dieteren, I. E. M., and Buurman, W. A. Cross-linking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-FcγR interactions. J. Immunol., 144: 1304-1310, 1990.
34. Marsh, C. B., Gadek, J. E., Kindt, G. C., Moore, S. A., and Wewers, M. D. Monocyte Fcγ receptor cross-linking induces IL-8 production. J Immunol., 155: 3161-3167, 1995.
35. Deo, Y. M., Graziano, R. F., Repp, R., and van de Winkel, J. G. J. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today, 18: 127-135, 1997.